Skip to main content

Table 5 Description of MACE depending on prior antithrombotic therapy

From: Evaluation of therapy management and outcome in Takotsubo syndrome

  Study population n = 72
MACE No AT n = 3 AT n = 28 Dual AT n = 29 OAC n = 6 AT + OAC n = 4 Triple therapy n = 2
No event 2 (3%) 25 (35%) 25 (35%) 5 (7%) 4 (6%) 2 (3%)
With Event 1 (1%) 3 (4%) 4 (6%) 1 (1%) 0 0
Myocardial infarction 0 1 (1%) 0 0 0 0
Stroke 0 1 (1%) 1 (1%) 1 (1%) 0 0
Recurrence of TTS 0 0 1 (1%) 0 0 0
Death 1 (1%) 1 (1%) 2 (3%) 0 0 0
  1. Data is presented as number of patients and percentage
  2. MACE major adverse cardiac event, AT antiplatelet therapy, OAC anticoagulation therapy